These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17288678)

  • 1. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
    Armstrong EP; Skrepnek GH; Haim Erder M
    Curr Med Res Opin; 2007 Feb; 23(2):251-8. PubMed ID: 17288678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the comparative-effectiveness of antidepressants commonly prescribed for depression in the US Medicare population.
    Kaplan C; Zhang Y
    J Ment Health Policy Econ; 2012 Dec; 15(4):171-8. PubMed ID: 23525835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial.
    Ventura D; Armstrong EP; Skrepnek GH; Haim Erder M
    Curr Med Res Opin; 2007 Feb; 23(2):245-50. PubMed ID: 17288677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on the pharmacoeconomics of escitalopram in depression.
    Croom KF; Plosker GL
    CNS Drugs; 2004; 18(7):469-73. PubMed ID: 15139801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.
    Armstrong EP; Malone DC; Erder MH
    Curr Med Res Opin; 2008 Apr; 24(4):1115-21. PubMed ID: 18331669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
    Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
    J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
    Sullivan PW; Valuck R; Saseen J; MacFall HM
    CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges.
    McLaughlin TP; Eaddy MT; Grudzinski AN
    Clin Ther; 2004 Jan; 26(1):115-24. PubMed ID: 14996524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial results of the use of prescription order change forms to achieve dose form optimization (consolidation and tablet splitting) of SSRI antidepressants in a state Medicaid program.
    Hamer AM; Hartung DM; Haxby DG; Ketchum KL; Pollack DA
    J Manag Care Pharm; 2006; 12(6):449-56. PubMed ID: 16925452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A target trial emulation comparing the antidepressant effectiveness of selective serotonin reuptake inhibitors (SSRIs) highlighting the importance of patent-related confounding by indication.
    Rohde C; Hieronymus F; Østergaard SD
    Acta Psychiatr Scand; 2024 Oct; 150(4):198-208. PubMed ID: 38994727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
    Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
    Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression.
    Hemels ME; Kasper S; Walter E; Einarson TR
    Ann Pharmacother; 2004 Jun; 38(6):954-60. PubMed ID: 15113989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC; Bekele NB; Xu Y
    Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sertraline. A pharmacoeconomic evaluation of its use in depression.
    Davis R; Wilde MI
    Pharmacoeconomics; 1996 Oct; 10(4):409-31. PubMed ID: 10184609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.
    Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
    Adv Ther; 2013 Jul; 30(7):697-712. PubMed ID: 23929174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and efficacy of escitalopram and sertraline in post-stroke depression: a randomized controlled trial.
    Yan N; Hu S
    BMC Psychiatry; 2024 May; 24(1):365. PubMed ID: 38750479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice.
    Ekselius L; von Knorring L; Eberhard G
    Int Clin Psychopharmacol; 1997 Nov; 12(6):323-31. PubMed ID: 9547134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.